Onco-Innovations Limited (CNSX: ONCO)
Health Care · Biotechnology · CA
CA$0.32
-13.51% today · -77.1% 1Y
Onco-Innovations Limited (CNSX: ONCO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.60M and employs 1 people.
Over the last twelve months the share price has lost 77.1%, trading between 0.28 and 1.83.
Tweenvest scores Onco-Innovations Limited across four factors: quality 48/100, value 40/100. Its strongest factor is quality.
ONCO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.60M
- Revenue (TTM)
- $64.78K
- P/E
- —
- EPS
- -0.20
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CA$1.83
- 52-week low
- CA$0.28
- Avg volume (3M)
- —
- Shares outstanding
- 69.22M
- Employees
- 1
- Next earnings
- —
About Onco-Innovations Limited
Onco-Innovations Ltd. is a Canadian biotechnology company primarily focused on pioneering cancer research and developing oncology treatments. A significant offering in their portfolio is ONC010, a product specifically designed for use in cancer therapies. This enterprise was founded on September 16, 2021, and conducts its operations from its headquarters located in Calgary, Canada.
- ISIN
- CA68237C1059
- Listed since
- Nov 27, 2024
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Biotechnology Assets, S.A.BME: BST | $16.39M | €0.20 | +6.85% |
| aTyr Pharma, Inc.NasdaqCM: ATYR | $16.19M | $0.17 | -2.88% |
| Psyence Biomedical Ltd.NasdaqCM: PBM | $16.10M | $4.22 | -15.09% |
| TScan Therapeutics, Inc.NasdaqGM: TCRX | $15.66M | $0.23 | -2.94% |
| Xcell Therapeutics Inc.KOSDAQ: A373110 | $15.16M | ₩1,169.00 | +9.87% |
| Read-Gene S.A.WSE: RDG | $15.06M | zł4.96 | -1.59% |
| Dyadic International, Inc.NasdaqCM: DYAI | $14.98M | $0.41 | -7.43% |
| SenzaGen ABOM: SENZA | $14.97M | Skr4.56 | +1.10% |
Figures last refreshed Mar 19, 2025.